BioTechniques is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Journal
    • Aims and scope
    • Journal archive
    • Editorial board
    • For authors
    • Your editors: what do we do?

    Follow us on social media

  • Current issue
  • News
    • Latest news
    • Tech news
    • Events news
    • Company news

    Follow us on social media

  • Multimedia
    • Downloadable eBooks
    • Infographics
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • Features
    • Interviews
    • Opinion
    • In Focus
    • Spotlights
    • Companies
    • New products
    • Events

    Follow us on social media

  • Topics
    • Analytical chemistry
      • Biochemistry
      • Bioengineering and biophysics
      • Cancer research
      • Careers and Publishing
      • Cell and tissue biology
      • COVID-19
      • CRISPR
      • Computational biology
    • Diagnostics and preclinical
      • Drug discovery and development
      • Imaging
      • Immunology
      • Lab design and machinery
      • Microbiology
      • Molecular biology
    • Nanomedicine
      • Neuroscience
      • PCR and sequencing
      • Plant and climate science
      • Proteomics
      • Veterinary science
      • Whole-genome studies

    Follow us on social media

  • Become a member
Sign up for our webinar on enhancing protein purification efficiency! 1 days 18 hours 53 mins 20 secs Register here!

Reversing Alzheimer’s symptoms in mice with axitinib treatment

8 Oct 2021
Written by Ryan Gilroy (Commissioning Editor)
Drug discovery and development Neuroscience News

Alzheimer's and chemotherapy

Axitinib restored memory and cognitive function in mice that display symptoms of Alzheimer’s disease.

University of British Columbia (Canada) researchers demonstrated restoration of both memory and cognitive function in mice that display symptoms of Alzheimer’s disease by treatment with axitinib, a common chemotherapy drug.

READ MORE ON NEURO CENTRAL NOW

Top content

  • PFAS versus the gut microbiome
  • Novel nanocarrier could transform therapeutic antibody delivery
  • A super-resolution view of lipid nanoparticles

Related tags

Alzheimer's Disease chemotherapy
Previous article Next article

Related articles

12 SEP 2022 CANCER RESEARCH

Old drug learns new tricks against small-cell lung cancer

15 NOV 2023 DIAGNOSTICS AND PRECLINICAL

Non-invasive diagnosis of Alzheimer’s disease from saliva samples

Alzheimer’s disease Neuron Neuro IF
18 SEP 2020 NEUROSCIENCE

Understanding Alzheimer’s disease: answering some frequently asked questions

14 FEB 2025 CELL AND TISSUE BIOLOGY

Mitochondria of memory: the mitochondrial process supporting social recognition

23 SEP 2024 PROTEOMICS

Novel tau therapies show promise for Alzheimer’s

BioTechniques journal logo feature image
3 MAR 2025 CRISPR

How are CRISPR screening methods uncovering new insights into the functional basis of neurodevelopment and neurodegeneration? – Find out in your latest issue of BioTechniques

  • About BioTechniques
  • Advisory Board
  • Contact Us
  • Advertising
  • Permissions
  • Whitelist Emails
  • Press release policy
  • Accessibility
Contact
Contact Us
Office info

BioTechniques is powered by Taylor & Francis Group

BioTechniques, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom

Impact Factor 2.2 | CiteScore 2.0

  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 BioTechniques